首页> 外文期刊>Journal of chromatography, B. Analytical technologies in the biomedical and life sciences >Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection
【24h】

Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection

机译:液相色谱-质谱联用法测定人和小鼠血浆中的环二肽FK228

获取原文
获取原文并翻译 | 示例
       

摘要

An analytical method was developed and validated for the quantitative determination of the cyclic depsipeptide FK228 (romidepsin, formerly FR901228; NSC 630176), a histone deacetylase inhibitor, in human and mouse plasma. Calibration curves were linear in the concentration range of 2-1000 ng/mL. Sample pretreatment involved a liquid-liquid extraction of 0.1 mL aliquots of plasma with ethyl acetate. FK228 and the internal standard, harmine, were separated on a Zorbax SB C18 column (75 mm x 2.1 mm, 3.5 mu m), using a mobile phase composed of methanol and 0.2% formic acid. The column eluent was monitored by mass spectrometry with electrospray ionization. Accuracy and precision of four concentrations of quality control samples ranged from 101.5 to 106.4% and 0.7 to 3.5% in human plasma and 93.6 to 100.6% and 0.6 to 6.5%, in mouse plasma, respectively. This method represents a significant improvement over our previously published analytical assay for this agent, decreasing the sample volume requirements, increasing the accuracy and precision (through addition of a suitable internal standard), expanding the analytical range and validating in additional biological matrices. The developed method was applied to study the pharmacokinetics of FK228 in over 1000 clinical and preclinical samples. (c) 2008 Elsevier B.V. All rights reserved.
机译:开发了一种分析方法,并已用于定量测定人和小鼠血浆中的组蛋白脱乙酰基酶抑制剂环磷酸二肽FK228(romidepsin,以前为FR901228; NSC 630176)。校准曲线在2-1000 ng / mL的浓度范围内呈线性。样品预处理涉及用乙酸乙酯液-液萃取0.1 mL等分试样的血浆。在Zorbax SB C18色谱柱(75 mm x 2.1 mm,3.5μm)上使用由甲醇和0.2%甲酸组成的流动相分离FK228和内标harmine。通过质谱与电喷雾电离监测柱洗脱液。四种浓度的质量控制样品的准确度和精密度在人血浆中分别为101.5%至106.4%和0.7至3.5%,在小鼠血浆中分别为93.6%至100.6%和0.6至6.5%。该方法相对于我们先前发布的对该试剂的分析方法进行了重大改进,减少了样品量要求,提高了准确性和精密度(通过添加合适的内标),扩展了分析范围并在其他生物基质中进行了验证。所开发的方法用于研究FK228在1000多个临床和临床前样品中的药代动力学。 (c)2008 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号